Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment

Massimiliano Mirabella, Assunta Bianco, Agata Katia Patanella, Viviana Nociti, Chiara De Fino, Matteo Lucchini, Paolo Maria Rossini

Risultato della ricerca: Contributo in rivistaArticolo in rivista

3 Citazioni (Scopus)

Abstract

In phase II clinical trial, fingolimod at a dose of 5.0 mg (ten times higher than the currently approved dose) induced dyspnoea and decreased forced expiratory flow in some patients, probably trought an airways constriction S1P4-mediated. In phase III trials, respiratory adverse events associated with fingolimod treatment as dyspnoea, cough, oropharingeal pain and nasal congestion are reported with the same incidence of placebo. Here we report two cases of severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment, which led to permanent treatment withdrawal.
Lingua originaleEnglish
pagine (da-a)11-13
Numero di pagine3
RivistaMultiple Sclerosis and Related Disorders
Volume9
DOI
Stato di pubblicazionePubblicato - 2016

Keywords

  • Adverse event
  • Fingolimod
  • Multiple sclerosis
  • Neurology
  • Neurology (clinical)
  • Respiratory
  • Side effect

Fingerprint Entra nei temi di ricerca di 'Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment'. Insieme formano una fingerprint unica.

Cita questo